BidaskClub Downgrades Albireo Pharma (ALBO) to Sell

Albireo Pharma (NASDAQ:ALBO) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.

Several other analysts also recently commented on ALBO. Zacks Investment Research downgraded shares of Albireo Pharma from a “hold” rating to a “sell” rating in a report on Thursday, November 15th. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 target price on shares of Albireo Pharma in a report on Tuesday, November 13th. ValuEngine downgraded shares of Albireo Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Cowen reiterated a “buy” rating on shares of Albireo Pharma in a report on Wednesday, November 14th. Finally, Wedbush reiterated a “buy” rating and issued a $69.00 target price on shares of Albireo Pharma in a report on Friday, January 25th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $51.25.

Shares of ALBO stock opened at $26.00 on Tuesday. The stock has a market capitalization of $311.46 million, a PE ratio of -8.21 and a beta of 1.74. Albireo Pharma has a one year low of $19.10 and a one year high of $39.35.

Albireo Pharma (NASDAQ:ALBO) last announced its earnings results on Tuesday, November 13th. The biopharmaceutical company reported ($1.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.20). The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $1.55 million. As a group, sell-side analysts expect that Albireo Pharma will post -3.7 EPS for the current year.

Several hedge funds have recently made changes to their positions in ALBO. Wells Fargo & Company MN increased its holdings in Albireo Pharma by 315.3% during the third quarter. Wells Fargo & Company MN now owns 4,676 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 3,550 shares during the last quarter. MetLife Investment Advisors LLC increased its holdings in Albireo Pharma by 55.1% during the third quarter. MetLife Investment Advisors LLC now owns 7,312 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 2,599 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Albireo Pharma by 83.3% during the third quarter. Acadian Asset Management LLC now owns 8,513 shares of the biopharmaceutical company’s stock worth $281,000 after buying an additional 3,868 shares during the last quarter. Rhumbline Advisers increased its holdings in Albireo Pharma by 40.2% during the fourth quarter. Rhumbline Advisers now owns 13,056 shares of the biopharmaceutical company’s stock worth $320,000 after buying an additional 3,743 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in Albireo Pharma during the second quarter worth about $476,000. Institutional investors own 66.61% of the company’s stock.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Read More: Capital Gains

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply